Shares of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) have been given a consensus recommendation of “Buy” by the nine analysts that are presently covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $111.20.
A number of equities analysts have weighed in on the stock. Wolfe Research assumed coverage on shares of Enanta Pharmaceuticals in a research note on Friday, May 24th. They set an “outperform” rating and a $117.00 target price for the company. BidaskClub raised shares of Zumiez from a “sell” rating to a “hold” rating in a research note on Saturday, June 22nd. Zacks Investment Research raised shares of Garrett Motion from a “sell” rating to a “hold” rating in a research note on Friday, May 10th. Finally, Berenberg Bank set a €126.00 ($146.51) target price on shares of Nemetschek and gave the company a “neutral” rating in a research note on Tuesday, April 23rd.
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Oregon Public Employees Retirement Fund bought a new stake in shares of Enanta Pharmaceuticals during the fourth quarter valued at approximately $424,000. PNC Financial Services Group Inc. grew its position in Enanta Pharmaceuticals by 64.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 634 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 249 shares during the period. Texas Permanent School Fund grew its position in Enanta Pharmaceuticals by 4.3% in the fourth quarter. Texas Permanent School Fund now owns 10,296 shares of the biotechnology company’s stock valued at $729,000 after acquiring an additional 420 shares during the period. Los Angeles Capital Management & Equity Research Inc. grew its position in Enanta Pharmaceuticals by 17.9% in the fourth quarter. Los Angeles Capital Management & Equity Research Inc. now owns 4,290 shares of the biotechnology company’s stock valued at $304,000 after acquiring an additional 650 shares during the period. Finally, Citigroup Inc. grew its position in Enanta Pharmaceuticals by 875.0% in the fourth quarter. Citigroup Inc. now owns 69,495 shares of the biotechnology company’s stock valued at $4,922,000 after acquiring an additional 62,367 shares during the period. 89.49% of the stock is owned by institutional investors.
Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported $0.20 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.09) by $0.29. Enanta Pharmaceuticals had a net margin of 33.28% and a return on equity of 19.25%. The business had revenue of $39.60 million during the quarter, compared to analyst estimates of $40.92 million. During the same period last year, the business posted $0.61 earnings per share. Enanta Pharmaceuticals’s quarterly revenue was down 10.0% compared to the same quarter last year. On average, analysts predict that Enanta Pharmaceuticals will post 1.9 EPS for the current year.
Enanta Pharmaceuticals Company Profile
Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.
Recommended Story: What is the return on assets (ROA) ratio?
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.